

IXICO PLC

13:36 18 Feb 2013

Phytopharm plummets on phase II trial disappointment

Phytopharm (LON:PYM) shares fell out of bed with a bang this morning after a setback on its Parkinson's disease treatment, Cogane.

Analysis of the headline results from a Phase II trial in unmedicated patients with early-stage Parkinson's disease indicated that Cogane had no beneficial effects on patients' symptoms measured by the primary or secondary endpoints in the study.

Review of the safety data confirmed that Cogane administered orally once daily for up to 28 weeks was well tolerated.

The full results of the study will be published in an appropriate scientific forum in due course.

Professor Warren Olanow, professor of Neurology and Neuroscience at Mount Sinai Medical School and co-chief investigator for the study expressed disappointment at the result.

"Trophic factors that enhance and restore function to remaining nerve cells is an extremely promising approach for the treatment of neurodegenerative disorders such as Parkinson's disease. Cogane offered the potential of providing trophic effects throughout the brain with an oral medication that was relatively safe and well tolerated. The company is to be congratulated for carrying out this important study in such a high quality manner. Sadly, the results are negative," Professor Olanow said.

"We are naturally disappointed with the outcome of this study of Cogane in patients with Parkinson's disease. Cogane had demonstrated encouraging efficacy in a wide range of industry standard pre-clinical models but this promise has not translated into clinically meaningful efficacy in this study," said Tim Sharpington, chief executive officer of Phytopharm.

"Cogane's future now looks bleak – we do not view potential development for amyotrophic lateral sclerosis (ALS) as viable – and we are not surprised the stock is trading close to Phytopharm's £5.5m cash balance," said Edison Research.

"The company is conducting a strategic review and we believe the best outcome may be a reverse merger by a private company seeking to utilise Phytopharm's cash, LSE listing and £55m in accumulated tax losses," the research house added.

Shares in Phytopharm were down by 81% to 1,92p in afternoon trading.

Price: 90

Market Cap: £42.56 m

1 Year Share Price Graph



February 2012 August 2012 February 2013

Share Information

Code: IXI

Listing: AIM

52 week	High	Low
	127	41.5

Sector: Pharma & Biotech

Website: www.ixico.com

Company Synopsis:

IXICO is a fast growing and profitable medical data analytics company, providing data management and advanced analytics to the pharmaceutical clinical trials market.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).